Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 2 pages · Chinese
Release
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Announcement on Renewing Engagement of Accounting Firm
- Announcement on Receiving the Clinical Trial Approval Notice for Qingshen Tongluo Granules
- Announcement on Appointment of Deputy General Manager
- Announcement on Receiving the Clinical Trial Approval Notice for Heihuang Chizhu Granules
- Announcement on the Receipt of the Clinical Trial Approval Notice for Yunpi Huatan Tongqiao Granules
Later from Jiangsu Kanion Pharmaceutical
- Report for Q1 2026
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit
- Announcement on Cancellation of Repurchased Shares and Notification to Creditors
- Announcement on Progress in Repurchasing Shares through Call Auction
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical